Who are ALD403 (Eptinezumab)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fremanezumab Prefilled Syringe [Ajovy], erenumab-aooe, Fremanezumab Prefilled Syringe, Erenumab Dose 1, ALD403.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ald403-eptinezumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ALD403 (Eptinezumab) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ALD403 (Eptinezumab) (ALD403 (Eptinezumab)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CGRP monoclonal antibody. Area: Neurology.

phase 3 CGRP monoclonal antibody CGRP (Calcitonin Gene-Related Peptide) Neurology Biologic Live · refreshed every 30 min

Target snapshot

ALD403 (Eptinezumab) (ALD403 (Eptinezumab)) — Alder Biopharmaceuticals, Inc.. Eptinezumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ALD403 (Eptinezumab) TARGET	ALD403 (Eptinezumab)	Alder Biopharmaceuticals, Inc.	phase 3	CGRP monoclonal antibody	CGRP (Calcitonin Gene-Related Peptide)
Fremanezumab Prefilled Syringe [Ajovy]	Fremanezumab Prefilled Syringe [Ajovy]	Beth Israel Deaconess Medical Center	marketed	CGRP monoclonal antibody	Calcitonin gene-related peptide (CGRP)
erenumab-aooe	erenumab-aooe	Amgen	marketed	CGRP monoclonal antibody antagonist	Calcitonin gene-related peptide (CGRP)
Fremanezumab Prefilled Syringe	Fremanezumab Prefilled Syringe	Hospital Clínico Universitario de Valladolid	marketed	CGRP monoclonal antibody	CGRP (Calcitonin Gene-Related Peptide)
Erenumab Dose 1	Erenumab Dose 1	Amgen	phase 3	CGRP monoclonal antibody	CGRP (Calcitonin Gene-Related Peptide)
ALD403	ALD403	Alder Biopharmaceuticals, Inc.	phase 3	CGRP monoclonal antibody	CGRP (Calcitonin Gene-Related Peptide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CGRP monoclonal antibody class)

Alder Biopharmaceuticals, Inc. · 2 drugs in this class
Amgen · 1 drug in this class
Beth Israel Deaconess Medical Center · 1 drug in this class
Hospital Clínico Universitario de Valladolid · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALD403 (Eptinezumab) — Competitive Intelligence Brief. https://druglandscape.com/ci/ald403-eptinezumab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing